Skip to main content

Acarbose Disease Interactions

There are 5 disease interactions with acarbose.

Major

Acarbose (applies to acarbose) cirrhosis

Major Potential Hazard, Moderate plausibility.

The use of acarbose is contraindicated in patients with primary cirrhosis.

References

  1. (2001) "Product Information. Precose (acarbose)." Bayer
Major

Acarbose (applies to acarbose) renal dysfunction

Major Potential Hazard, Moderate plausibility.

Acarbose may accumulate in patients with renal impairment. Following oral administration, 35% of a dose is recovered in the urine as either the parent drug or metabolites. However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted. Therapy with acarbose should be administered cautiously in patients with renal dysfunction. The manufacturer does not recommend its use in patients with significantly impaired renal function.

References

  1. Clissold SP, Edwards C (1988) "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs, 35, p. 214-43
  2. Balfour JA, McTavish D (1993) "Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus [published erratum appears in Drugs 1994 Dec;48(6):929]." Drugs, 46, p. 1025-54
  3. (2001) "Product Information. Precose (acarbose)." Bayer
Major

Alpha-glucosidase inhibitors (applies to acarbose) diabetic ketoacidosis

Major Potential Hazard, Moderate plausibility.

The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.

References

  1. (2001) "Product Information. Precose (acarbose)." Bayer
  2. (2001) "Product Information. Glyset (miglitol)." Bayer
Major

Alpha-glucosidase inhibitors (applies to acarbose) intestinal disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colonic Ulceration, Intestinal Obstruction, Malabsorption Syndrome, Colitis/Enteritis (Noninfectious)

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

References

  1. Hollander P (1992) "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs, 44 Suppl 3, p. 47-53
  2. Clissold SP, Edwards C (1988) "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs, 35, p. 214-43
  3. (2001) "Product Information. Precose (acarbose)." Bayer
  4. Nishii Y, Aizawa T, Hashizume K (1996) "Ileus: a rare side effect of acarbose." Diabetes Care, 19, p. 1033
  5. (2001) "Product Information. Glyset (miglitol)." Bayer
View all 5 references
Moderate

Acarbose (applies to acarbose) liver disease

Moderate Potential Hazard, Moderate plausibility.

The use of acarbose has been associated with dose-related elevations in serum transaminase levels and, rarely, hyperbilirubinemia and jaundice. Hepatic adverse effects may be more likely to occur at dosages exceeding 50 mg three times a day. Therapy with acarbose should be administered cautiously in patients with liver disease. Monitoring of serum transaminases is recommended every 3 months during the first year of treatment and periodically thereafter. If hepatotoxicity is suspected at any time, a dosage reduction or withdrawal of therapy may be indicated.

References

  1. Hollander P (1992) "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs, 44 Suppl 3, p. 47-53
  2. Clissold SP, Edwards C (1988) "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs, 35, p. 214-43
  3. Balfour JA, McTavish D (1993) "Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus [published erratum appears in Drugs 1994 Dec;48(6):929]." Drugs, 46, p. 1025-54
  4. (2001) "Product Information. Precose (acarbose)." Bayer
  5. Andrade RJ, Lucena MI, Rodriguezmendizabal M (1996) "Hepatic injury caused by acarbose." Ann Intern Med, 124, p. 931
View all 5 references

Acarbose drug interactions

There are 270 drug interactions with acarbose.

Acarbose alcohol/food interactions

There is 1 alcohol/food interaction with acarbose.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer